KR20220075210A - Tcr 유전자를 단리하기 위한 방법 - Google Patents
Tcr 유전자를 단리하기 위한 방법 Download PDFInfo
- Publication number
- KR20220075210A KR20220075210A KR1020227004120A KR20227004120A KR20220075210A KR 20220075210 A KR20220075210 A KR 20220075210A KR 1020227004120 A KR1020227004120 A KR 1020227004120A KR 20227004120 A KR20227004120 A KR 20227004120A KR 20220075210 A KR20220075210 A KR 20220075210A
- Authority
- KR
- South Korea
- Prior art keywords
- tcr
- cells
- cell
- antigen
- library
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 448
- 108090000623 proteins and genes Proteins 0.000 title claims description 75
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 930
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 908
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 292
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 280
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 280
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 66
- 210000004027 cell Anatomy 0.000 claims description 743
- 239000000427 antigen Substances 0.000 claims description 382
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 377
- 239000002773 nucleotide Substances 0.000 claims description 276
- 125000003729 nucleotide group Chemical group 0.000 claims description 272
- 108091007433 antigens Proteins 0.000 claims description 269
- 102000036639 antigens Human genes 0.000 claims description 269
- 230000014509 gene expression Effects 0.000 claims description 155
- 239000000523 sample Substances 0.000 claims description 131
- 206010028980 Neoplasm Diseases 0.000 claims description 124
- 239000003550 marker Substances 0.000 claims description 114
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 95
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 83
- 230000004913 activation Effects 0.000 claims description 80
- 150000001413 amino acids Chemical class 0.000 claims description 60
- 108020004414 DNA Proteins 0.000 claims description 59
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 54
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 54
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 47
- 238000002955 isolation Methods 0.000 claims description 43
- 210000001519 tissue Anatomy 0.000 claims description 42
- 230000006044 T cell activation Effects 0.000 claims description 40
- 238000003501 co-culture Methods 0.000 claims description 40
- 238000012163 sequencing technique Methods 0.000 claims description 38
- 230000004044 response Effects 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 34
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 26
- 230000011664 signaling Effects 0.000 claims description 23
- 238000013459 approach Methods 0.000 claims description 22
- 230000009257 reactivity Effects 0.000 claims description 22
- 239000011324 bead Substances 0.000 claims description 21
- -1 CD137 Proteins 0.000 claims description 19
- 230000001419 dependent effect Effects 0.000 claims description 19
- 230000004068 intracellular signaling Effects 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 230000003321 amplification Effects 0.000 claims description 17
- 230000003902 lesion Effects 0.000 claims description 17
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 108091033409 CRISPR Proteins 0.000 claims description 16
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 16
- 102100033467 L-selectin Human genes 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 229950010131 puromycin Drugs 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 102100037850 Interferon gamma Human genes 0.000 claims description 14
- 108010074328 Interferon-gamma Proteins 0.000 claims description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 14
- 102000000588 Interleukin-2 Human genes 0.000 claims description 14
- 238000000684 flow cytometry Methods 0.000 claims description 14
- 230000001404 mediated effect Effects 0.000 claims description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 13
- 230000004186 co-expression Effects 0.000 claims description 13
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 12
- 108700008625 Reporter Genes Proteins 0.000 claims description 12
- 230000004663 cell proliferation Effects 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 238000010361 transduction Methods 0.000 claims description 12
- 230000026683 transduction Effects 0.000 claims description 12
- 238000012546 transfer Methods 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 11
- 230000000638 stimulation Effects 0.000 claims description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 238000010354 CRISPR gene editing Methods 0.000 claims description 9
- 230000003115 biocidal effect Effects 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 238000002864 sequence alignment Methods 0.000 claims description 9
- 238000001712 DNA sequencing Methods 0.000 claims description 8
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 8
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 8
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000007403 mPCR Methods 0.000 claims description 8
- 210000004986 primary T-cell Anatomy 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 101710163270 Nuclease Proteins 0.000 claims description 7
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 7
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 7
- 230000005784 autoimmunity Effects 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 238000011275 oncology therapy Methods 0.000 claims description 7
- 230000019491 signal transduction Effects 0.000 claims description 7
- 230000002103 transcriptional effect Effects 0.000 claims description 7
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 239000002458 cell surface marker Substances 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 230000010354 integration Effects 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 108700010070 Codon Usage Proteins 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- 230000001131 transforming effect Effects 0.000 claims description 5
- 108010057466 NF-kappa B Proteins 0.000 claims description 4
- 238000003559 RNA-seq method Methods 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 238000005457 optimization Methods 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 3
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims description 3
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims description 3
- 208000005228 Pericardial Effusion Diseases 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 3
- 230000003187 abdominal effect Effects 0.000 claims description 3
- 210000003567 ascitic fluid Anatomy 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000003097 mucus Anatomy 0.000 claims description 3
- 210000004912 pericardial fluid Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000004910 pleural fluid Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000004911 serous fluid Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101710112752 Cytotoxin Proteins 0.000 claims description 2
- 238000007399 DNA isolation Methods 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 238000002123 RNA extraction Methods 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- 238000013467 fragmentation Methods 0.000 claims description 2
- 238000006062 fragmentation reaction Methods 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract description 3
- 238000001994 activation Methods 0.000 description 64
- 238000012216 screening Methods 0.000 description 60
- 102000004169 proteins and genes Human genes 0.000 description 27
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 25
- 229930189065 blasticidin Natural products 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 18
- 238000013461 design Methods 0.000 description 17
- 206010009944 Colon cancer Diseases 0.000 description 15
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 15
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 238000010586 diagram Methods 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 9
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 9
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 9
- 108091008875 B cell receptors Proteins 0.000 description 8
- 206010033128 Ovarian cancer Diseases 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 101000775015 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Cyclomaltodextrinase Proteins 0.000 description 8
- 238000010201 enrichment analysis Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 108700005077 Viral Genes Proteins 0.000 description 6
- 230000037433 frameshift Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 101000648659 Homo sapiens Transmembrane gamma-carboxyglutamic acid protein 3 Proteins 0.000 description 5
- 101000764634 Homo sapiens Transmembrane gamma-carboxyglutamic acid protein 4 Proteins 0.000 description 5
- 102100028870 Transmembrane gamma-carboxyglutamic acid protein 3 Human genes 0.000 description 5
- 102100026222 Transmembrane gamma-carboxyglutamic acid protein 4 Human genes 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 231100000221 frame shift mutation induction Toxicity 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 238000000126 in silico method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 3
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 3
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 101150076349 PRRG1 gene Proteins 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 102100028865 Transmembrane gamma-carboxyglutamic acid protein 1 Human genes 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 238000010448 genetic screening Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 238000012418 validation experiment Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 230000008826 genomic mutation Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000010234 longitudinal analysis Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007860 single-cell PCR Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108010008955 Chemokine CXCL13 Proteins 0.000 description 1
- 102000006574 Chemokine CXCL13 Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010041504 Costimulatory and Inhibitory T-Cell Receptors Proteins 0.000 description 1
- 102000000529 Costimulatory and Inhibitory T-Cell Receptors Human genes 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 208000033878 Tertiary Lymphoid Structures Diseases 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102100022748 Wilms tumor protein Human genes 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000037438 passenger mutation Effects 0.000 description 1
- 230000006045 positive regulation of cell activation Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 102200104847 rs28934574 Human genes 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Ecology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874125P | 2019-07-15 | 2019-07-15 | |
| US62/874,125 | 2019-07-15 | ||
| US202062975924P | 2020-02-13 | 2020-02-13 | |
| US62/975,924 | 2020-02-13 | ||
| US202063024341P | 2020-05-13 | 2020-05-13 | |
| US63/024,341 | 2020-05-13 | ||
| US202063034157P | 2020-06-03 | 2020-06-03 | |
| US63/034,157 | 2020-06-03 | ||
| US202063039346P | 2020-06-15 | 2020-06-15 | |
| US63/039,346 | 2020-06-15 | ||
| PCT/US2020/041824 WO2021011482A1 (en) | 2019-07-15 | 2020-07-13 | Method to isolate tcr genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220075210A true KR20220075210A (ko) | 2022-06-07 |
Family
ID=74211262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227004120A Pending KR20220075210A (ko) | 2019-07-15 | 2020-07-13 | Tcr 유전자를 단리하기 위한 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210040558A1 (https=) |
| EP (1) | EP3999528A4 (https=) |
| JP (1) | JP2022541181A (https=) |
| KR (1) | KR20220075210A (https=) |
| CN (1) | CN114502579A (https=) |
| AU (1) | AU2020315325A1 (https=) |
| BR (1) | BR112022000790A2 (https=) |
| CA (1) | CA3146845A1 (https=) |
| CL (1) | CL2022000085A1 (https=) |
| MX (1) | MX2022000667A (https=) |
| TW (1) | TW202117014A (https=) |
| WO (1) | WO2021011482A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| AU2021320556A1 (en) | 2020-08-07 | 2023-03-09 | Neogene Therapeutics B.V. | Methods to enrich genetically engineered T cells |
| TW202242097A (zh) | 2021-01-20 | 2022-11-01 | 荷蘭商新基因治療公司 | 經工程化之抗原呈現細胞 |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| WO2023010436A1 (zh) * | 2021-08-05 | 2023-02-09 | 卡瑞济(北京)生命科技有限公司 | Tcr表达构建体以及其制备方法和用途 |
| WO2023114994A1 (en) * | 2021-12-16 | 2023-06-22 | Board Of Regents, The University Of Texas System | Personalized ranking and identification of onco-reactive t cell receptors and uses thereof |
| CN114134221B (zh) * | 2022-01-28 | 2022-04-08 | 北京肿瘤医院(北京大学肿瘤医院) | 一种筛选肿瘤特异tcr的方法 |
| US20250216381A1 (en) * | 2022-03-21 | 2025-07-03 | Alaunos Therapeutics, Inc. | Methods for Identifying Neoantigen-Reactive T Cell Receptors |
| CN115341020A (zh) * | 2022-08-29 | 2022-11-15 | 深圳市美星生物科技有限公司 | 一种利用lamp技术的急性心梗和心衰外显子测序方法 |
| EP4638712A2 (en) * | 2022-12-22 | 2025-10-29 | Bluesphere Bio, Inc. | Methods for identifying t cell receptors (tcrs) that bind antigens |
| WO2024163607A2 (en) * | 2023-02-02 | 2024-08-08 | Board Of Regents, The University Of Texas System | T-cell receptors targeting egfr and methods of use thereof |
| EP4550335A1 (en) * | 2023-10-31 | 2025-05-07 | Tempus AI, Inc. | T cell receptor screening methods |
| WO2025213105A1 (en) * | 2024-04-04 | 2025-10-09 | Biontech Us Inc. | Methods for identifying t-cell receptor (tcr) sequences |
| WO2025240737A1 (en) * | 2024-05-16 | 2025-11-20 | Rutgers, The State University Of New Jersey | Methods of producing memory t cells in vitro and their use in immunotherapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102480188B1 (ko) * | 2012-09-14 | 2022-12-21 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체 |
| EP3234130B1 (en) * | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| JP2019516768A (ja) * | 2016-05-25 | 2019-06-20 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | がんの治療のための免疫チェックポイント阻害剤及び細胞傷害性ｔ細胞 |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
-
2020
- 2020-07-13 BR BR112022000790A patent/BR112022000790A2/pt unknown
- 2020-07-13 AU AU2020315325A patent/AU2020315325A1/en not_active Abandoned
- 2020-07-13 MX MX2022000667A patent/MX2022000667A/es unknown
- 2020-07-13 KR KR1020227004120A patent/KR20220075210A/ko active Pending
- 2020-07-13 JP JP2022502277A patent/JP2022541181A/ja active Pending
- 2020-07-13 WO PCT/US2020/041824 patent/WO2021011482A1/en not_active Ceased
- 2020-07-13 CN CN202080064806.0A patent/CN114502579A/zh active Pending
- 2020-07-13 CA CA3146845A patent/CA3146845A1/en active Pending
- 2020-07-13 EP EP20841220.5A patent/EP3999528A4/en active Pending
- 2020-07-13 US US16/927,661 patent/US20210040558A1/en not_active Abandoned
- 2020-07-15 TW TW109123978A patent/TW202117014A/zh unknown
-
2022
- 2022-01-12 CL CL2022000085A patent/CL2022000085A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3999528A1 (en) | 2022-05-25 |
| JP2022541181A (ja) | 2022-09-22 |
| EP3999528A4 (en) | 2023-10-25 |
| CN114502579A (zh) | 2022-05-13 |
| CA3146845A1 (en) | 2021-01-21 |
| WO2021011482A1 (en) | 2021-01-21 |
| US20210040558A1 (en) | 2021-02-11 |
| AU2020315325A1 (en) | 2022-02-17 |
| BR112022000790A2 (pt) | 2022-04-12 |
| TW202117014A (zh) | 2021-05-01 |
| CL2022000085A1 (es) | 2022-09-20 |
| MX2022000667A (es) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20220075210A (ko) | Tcr 유전자를 단리하기 위한 방법 | |
| KR20220105664A (ko) | Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도 | |
| EP3704229B1 (en) | Process for producing a t cell composition | |
| US20210102942A1 (en) | High-throughput method to screen cognate T cell and epitope reactivities in primary human cells | |
| US11534461B2 (en) | High affinity merkel cell polyomavirus T antigen-specific TCRS and uses thereof | |
| WO2019183610A9 (en) | Tissue resident memory cell profiles, and uses thereof | |
| US20250216381A1 (en) | Methods for Identifying Neoantigen-Reactive T Cell Receptors | |
| Füchsl et al. | High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells | |
| US20220228164A1 (en) | Engineered antigen presenting cells | |
| Khateb et al. | Rapid enrichment of progenitor exhausted neoantigen-specific CD8 T cells from peripheral blood | |
| WO2024182219A1 (en) | Therapeutic t cell receptors targeting kras g12d | |
| CN121335919A (zh) | 结合呈递的hpv16、mart1、cmv、ebv或流感肽的t细胞受体 | |
| EP4025595A1 (en) | Method to sequence mrna in single cells in parallel with quantification of intracellular phenotype | |
| US20250236915A1 (en) | Cd4+ t cell markers, compositions, and methods for cancer | |
| Soemardy | Single-Cell Functional Profiling for Cell Therapy Innovation Using the Nanovial Platform | |
| Hennig et al. | A new clustering approach identifies tumor-specific common TCRs with pan-cancer reactivity | |
| WO2025122800A9 (en) | Identification of neoantigen-reactive t cell receptors | |
| Dykema | DISTINCT TUMOR INFILTRATING TREG LINEAGES A ASSOCIATE WITH RESPONSE TO ANTI-PD1 (NIVOLUMAB) CHECKPOINT BLOCKADE IN NSCLC and IDENTIFYING CD4+ T CELL IMMUNITY ASSOCIATED WITH SARS-COV-2 INFECTION AND VACCINATION THROUGHOUT THE COVID-19 GLOBAL PANDEMIC | |
| HK40104698A (zh) | 工程化抗原呈递细胞 | |
| WO2024197072A2 (en) | Identification of neoantigen-reactive t cell receptors | |
| WO2023178140A2 (en) | Method for preparing t cells for adoptive t cell therapy | |
| Anandappa | Detecting Intratumoral T Cell Responses After Personal Neoantigen Vaccine in Glioblastoma Using a Novel T Cell Receptor Cloning and Expression System |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20220207 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application |